Passage BIO PASG

Passage Bio, Inc. is a clinical stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. The company focuses on developing one time gene therapies that target the underlying pathology of central nervous system disorders. Its lead product candidate, PBFT02, is an adeno associated virus serotype 1 based gene replacement therapy designed to raise progranulin levels in the brain and spinal cord. Passage Bio advances PBFT02 through clinical trials for frontotemporal dementia caused by progranulin deficiency and is exploring its use in additional neurodegenerative indications such as C9orf72 related frontotemporal dementia, amyotrophic lateral sclerosis and Alzheimer’s disease. The company also pursues a preclinical program for Huntington’s disease through its collaboration with Gemma Biotherapeutics.

Passage Bio currently generates revenue primarily through collaboration and licensing agreements rather than product sales. Under its agreement with Gemma Biotherapeutics, the company has received upfront payments, milestone payments and is entitled to receive additional development and commercial milestones as well as tiered royalties on future net sales. The company also receives reimbursement for transitional services provided to Gemma related to the transfer of previously outlicensed programs. No revenue is presently derived from commercial product sales as its candidates remain in clinical or preclinical development.

Passage Bio occupies a niche within the competitive gene therapy landscape focused on neurodegenerative diseases. Its main competitors in the frontotemporal dementia space include AviadoBio, which is advancing its own progranulin gene therapy, and Denali Therapeutics in partnership with Takeda, which is evaluating a recombinant progranulin protein. Other companies such as Voyager Therapeutics, uniQure and CRISPR based platforms are also pursuing therapies for related indications like Huntington’s disease and amyotrophic lateral sclerosis. Passage Bio differentiates itself through its proprietary adeno associated virus serotype 1 capsid, its intrathecal administration route that aims for broad brain distribution, and its emphasis on biomarkers such as cerebrospinal fluid progranulin and neurofilament light to guide development. The company has secured orphan drug and fast track designations from the U. S. Food and Drug Administration and similar orphan designation from the European Commission, which may provide regulatory and market exclusivity advantages.

Passage Bio’s current customers are primarily patients enrolled in its clinical trials and its collaborative partners. The company treats individuals suffering from frontotemporal dementia, C9orf72 related frontotemporal dementia, amyotrophic lateral sclerosis and Alzheimer’s disease in its studies. It works closely with Gemma Biotherapeutics for research, licensing and transitional services, and relies on Catalent for manufacturing and process development. Although no commercial product is yet available, the company anticipates serving patients, healthcare providers and payers once its therapies receive regulatory approval.